Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.

Autor:	Rasenack, Jens, Zeuzem, Stefan, Feinman, S Victor, Heathcote, E Jenny, Manns, Michael, Yoshida, Eric M, Swain, Mark G, Gane, Edward, Diago, Moises, Revicki, Dennis A, Lin, Amy, Wintfeld, Neil, Green, Jesse
Předmět:	THERAPEUTIC use of proteins ANTIVIRAL agents CLINICAL trials COMPARATIVE studies HEALTH status indicators HEALTH surveys RESEARCH methodology MEDICAL cooperation POLYETHYLENE glycol QUALITY of life QUESTIONNAIRES RECOMBINANT proteins RESEARCH EVALUATION research RANDOMIZED controlled trials TREATMENT effectiveness CHRONIC hepatitis C PSYCHOLOGY
Zdroj:	PharmacoEconomics; 2003, Vol. 21 Issue 5, p341-349, 9p
Abstrakt:	Background: Use of unmodified interferon alpha-2a in chronic hepatitis C is associated with impaired health-related quality of life during therapy. Treatment with peginterferon alpha-2a (40kD) provides an improved sustained response over unmodified interferon alpha-2a.Objectives: To compare health-related quality of life during treatment for patients receiving peginterferon alpha-2a (40kD) [Pegasys] versus unmodified interferon alpha-2a [Roferon].Design: A randomised, international, multicentre, open-label, parallel group study.Setting: 36 centres worldwide.Patients: Interferon-naïve patients (n = 531) with chronic hepatitis C.Interventions: Peginterferon alpha-2a (40kD) 180 mirog once a week (n = 267) for 48 weeks or unmodified interferon alpha-2a 6 million IU three times a week for 12 weeks followed by 36 weeks of 3 million IU three times a week (n = 264).Measurements: Fatigue Severity Scale and 36-item Short-Form Health Survey (SF-36).Results: At weeks 2 and 12, differences favouring peginterferon alpha-2a (40kD) were seen on seven of eight domains and both summary scores of the SF-36 (p < 0.05 to p < 0.01). At weeks 2, 12 and 24, patients receiving peginterferon alpha-2a (40kD) had less disabling fatigue (p < 0.01) than those receiving unmodified interferon alpha-2a.Conclusion: Treatment with peginterferon alpha-2a (40kD) is associated with less disabling fatigue and less impairment in patient functioning and well-being during treatment than unmodified interferon alpha-2a. In addition to safety and efficacy, the impact on health-related quality of life may be an important consideration for physicians when selecting an optimal treatment regimen. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink